IGF-1 LR3

What Is IGF-1 LR3?

IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor 1) is a synthetic, modified analog of IGF-1 with 83 amino acids (vs. 70 in native IGF-1). The modification includes a 13-amino acid N-terminal extension and an arginine substitution at position 3, which dramatically reduces binding to IGF binding proteins (IGFBPs). Since IGFBPs normally sequester IGF-1 and limit its bioavailability, IGF-1 LR3 has ~3x the potency and significantly longer half-life (~20-30 hours vs. ~12-15 hours for native IGF-1).

IGF-1 is the primary mediator of growth hormone's anabolic effects. While GH acts on the liver to produce IGF-1, direct administration of IGF-1 LR3 bypasses the GH axis entirely. This makes it fundamentally different from GH secretagogues — it provides the end-product rather than stimulating the body's own production.

IGF-1 LR3 is extremely potent and carries significant risks including severe hypoglycemia, organ growth, and potential cancer promotion. It is used primarily in research contexts and by athletes despite its risks.

What The Research Says

Research demonstrates IGF-1 LR3's potent anabolic effects: increased protein synthesis, enhanced nitrogen retention, and satellite cell activation in skeletal muscle. It promotes both hypertrophy and hyperplasia (new muscle cell formation) — the latter being unique among performance peptides.

The risks are also well-documented: IGF-1 promotes growth of all tissues, including potentially cancerous ones. Hypoglycemia can be severe and life-threatening. Acromegaly-like effects (jaw growth, organ enlargement) can occur with chronic use.

📚 Key Reference: PMID: 8769682 (IGF-1 LR3 pharmacology)

Common Uses

• Muscle growth research (research only)
• Growth factor biology research
• Burn/wound healing research

Important Safety Information

⚠️ SIGNIFICANT RISKS. Severe hypoglycemia (can be life-threatening — must eat carbohydrates around dosing). Gut distension and organ growth with chronic use. Potential cancer promotion (IGF-1 pathway is mitogenic). Not for unsupervised use. This is a high-risk research compound.

Questions To Ask Your Provider

1. What specific research application requires IGF-1 LR3 vs. GH secretagogues?
2. What hypoglycemia monitoring and management plan is in place?
3. Have cancer risk factors been assessed?
4. What is the source and purity?

Regulatory Status

NOT FDA-approved. Research use only. WADA prohibited. High-risk compound.